Atlas Trials

Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma

Clinical trial NCT05048017 · UNKNOWN

Trial details

NCT number
NCT05048017
Sponsor
Peking Union Medical College Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatocellular CarcinomaRegorafenibPD-1 Inhibitor
Start date
2021-10-01
Primary completion
2025-11-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.